中枢神経系バイオマーカーの市場規模、シェア、成長分析、タイプ別、用途別、エンドユーザー別、地域別 - 産業予測、2025年～2032年

中枢神経系バイオマーカーの世界市場規模は2023年に560万米ドルと評価され、予測期間（2025-2032年）のCAGRは8.1%で、2024年の605万米ドルから2032年には1,129万米ドルに成長する見通しです。

世界の中枢神経系バイオマーカー市場は、神経疾患の罹患率の上昇、人口の高齢化、ライフスタイルの進化に後押しされ、力強い成長を遂げています。この急成長により、正確な早期診断に対する需要が高まり、バイオマーカーに基づくツールの統合が促進されています。技術と調査の進歩により中枢神経系疾患の分子基盤が解明されつつあり、感度、特異性、予測力を高める革新的なバイオマーカーへの道が開かれつつあります。個別化医療への注目は、最適な患者群を特定し、治療反応を追跡するバイオマーカー解析の重要性を強調しています。製薬業界は医薬品開発や臨床試験においてこうしたバイオマーカーを重視する一方で、倫理的・規制的な懸念への対応に加え、標準化されたプロトコールや検証済みのアッセイの必要性などの課題に直面しています。全体として、この分野は神経学において変革的な発展を遂げようとしています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 規制情勢
• 特許分析

中枢神経系バイオマーカー市場規模：タイプ別& CAGR（2025-2032）

• 市場概要
• 安全性バイオマーカー
• 有効性バイオマーカー
• 検証バイオマーカー

中枢神経系バイオマーカー市場規模：用途別& CAGR（2025-2032）

• 市場概要
• 診断
  • アルツハイマー病
  • パーキンソン病
  • 多発性硬化症
  • 脳卒中
• 医薬品の発見と開発
  • 前臨床研究
  • 臨床試験
• パーソナライズ医療
  • ゲノムバイオマーカー
  • プロテオームバイオマーカー
  • メタボロミクスバイオマーカー

中枢神経系バイオマーカー市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院
• 診断検査室
• 調査機関
• バイオ医薬品企業

中枢神経系バイオマーカー市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• F. Hoffmann-La Roche Ltd（Switzerland）
• Novartis AG（Switzerland）
• Siemens Healthineers AG（Germany）
• Thermo Fisher Scientific Inc.（USA）
• Abbott Laboratories（USA）
• Merck KGaA（Germany）
• Eurofins Scientific（Luxembourg）
• Charles River Laboratories International, Inc.（USA）
• PerkinElmer Inc.（USA）
• Bio-Rad Laboratories, Inc.（USA）
• QIAGEN N.V.（Netherlands）
• Axon Neuroscience SE（Slovakia）
• Alector Inc.（USA）
• Oryzon Genomics S.A.（Spain）
• Banyan Biomarkers Inc.（USA）
• Avacta Group PLC（UK）
• Geno Technology Inc.（USA）
• Anavex Life Sciences Corp.（USA）
• Alseres Pharmaceuticals Inc.（USA）
• Aposense Ltd.（Israel）

結論と推奨事項

Global Central Nervous System Biomarkers Market size was valued at USD 5.6 million in 2023 and is poised to grow from USD 6.05 million in 2024 to USD 11.29 million by 2032, growing at a CAGR of 8.1% during the forecast period (2025-2032).

The global CNS biomarker market is witnessing robust growth, propelled by the rising incidence of neurological disorders, an aging population, and evolving lifestyles. This surge is prompting a heightened demand for precise, early diagnostics, fostering the integration of biomarker-based tools. Advances in technology and research are elucidating the molecular foundations of CNS disorders, paving the way for innovative biomarkers that enhance sensitivity, specificity, and predictive power. The focus on personalized medicine emphasizes the importance of biomarker analysis in identifying optimal patient groups and tracking treatment responses. While the pharmaceutical industry values these biomarkers for drug development and clinical trials, the market faces challenges including the need for standardized protocols and validated assays, along with addressing ethical and regulatory concerns. Overall, the sector is set for transformative developments in neurology.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Central Nervous System Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Central Nervous System Biomarkers Market Segmental Analysis

Global Central Nervous System Biomarkers Market is segmented by Type, Application, End-User and region. Based on Type, the market is segmented into Safety Biomarkers, Efficacy Biomarkers and Validation Biomarkers. Based on Application, the market is segmented into Diagnostics, Drug Discovery & Development and Personalized Medicine. Based on End-User, the market is segmented into Hospitals, Diagnostic Laboratories, Research Institutes and Biopharmaceutical Companies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Central Nervous System Biomarkers Market

The global market for Central Nervous System (CNS) biomarkers is significantly driven by the escalating incidence of neurological disorders, including conditions like Alzheimer's disease, Parkinson's disease, and multiple sclerosis. As the prevalence of these ailments continues to rise globally, there is an increasing need for precise and timely diagnostic solutions. This heightened demand emphasizes the importance of biomarker-based diagnostic tools, which are essential for early detection and management of CNS disorders. Consequently, the surge in the number of individuals affected by these conditions propels the growth of the CNS biomarkers market, highlighting the urgent necessity for innovative diagnostic advancements.

Restraints in the Global Central Nervous System Biomarkers Market

One significant restraint in the Global Central Nervous System (CNS) Biomarkers market is the intricate nature of CNS disorders. These conditions are typically characterized by their multifactorial aspects, which complicate the process of pinpointing reliable and specific biomarkers. The diversity and variability within CNS disorders create obstacles in establishing universal biomarkers that can effectively and accurately represent the underlying disease mechanisms. This complexity not only hampers the standardization of biomarker development but also adds to the challenges faced by researchers and healthcare professionals in diagnosing and monitoring CNS diseases, thereby impacting market growth.

Market Trends of the Global Central Nervous System Biomarkers Market

The Global Central Nervous System (CNS) Biomarkers market is experiencing a notable upward trend driven by rapid technological advancements. Innovations like high-throughput screening, next-generation sequencing, and sophisticated imaging techniques significantly enhance the sensitivity and specificity of biomarker detection and analysis. These improvements enable more accurate diagnoses and effective monitoring of CNS disorders, fostering better clinical outcomes. Moreover, as healthcare providers increasingly adopt these technologies, the demand for reliable and precise biomarkers is escalating. This trend is expected to fuel investment in research and development, ultimately positioning CNS biomarkers as a crucial element in personalized medicine and targeted therapies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Central Nervous System Biomarkers Market Size by Type & CAGR (2025-2032)

• Market Overview
• Safety Biomarkers
• Efficacy Biomarkers
• Validation Biomarkers

Global Central Nervous System Biomarkers Market Size by Application & CAGR (2025-2032)

• Market Overview
• Diagnostics
  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Stroke
• Drug Discovery & Development
  • Preclinical Studies
  • Clinical Trials
• Personalized Medicine
  • Genomic Biomarkers
  • Proteomic Biomarkers
  • Metabolomic Biomarkers

Global Central Nervous System Biomarkers Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Research Institutes
• Biopharmaceutical Companies

Global Central Nervous System Biomarkers Market Size & CAGR (2025-2032)

• North America (Type, Application, End-User)
  • US
  • Canada
• Europe (Type, Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories International, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axon Neuroscience SE (Slovakia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alector Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oryzon Genomics S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Banyan Biomarkers Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Avacta Group PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Geno Technology Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anavex Life Sciences Corp. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alseres Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aposense Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations